TuHURA Biosciences (HURA) Cash from Investing Activities (2020 - 2026)
TuHURA Biosciences (HURA) posted quarterly Cash from Investing Activities of -$48846.0 for Q1 2026, up 95.76% year-over-year from -$24952.4 in Q1 2025, and down 75.39% quarter-over-quarter from -$27850.0 in Q4 2025.
TuHURA Biosciences (HURA) Cash from Investing Activities (2020 - 2026) Analysis & Trends
TuHURA Biosciences' Cash from Investing Activities history runs 7 years deep, the most recent figure standing at -$48846.0 for Q1 2026.
- In Q1 2026, Cash from Investing Activities rose 95.76% year-over-year to -$48846.0; the TTM figure through Mar 2026 stood at -$233160.0 (up 96.38% YoY), while the FY2025 annual figure was -$1.3 million, up 77.94% from the prior year.
- Cash from Investing Activities for Q1 2026 stood at -$48846.0, down from -$27850.0 in the prior quarter.
- The five-year high for Cash from Investing Activities was -$20000.0 in Q4 2023, with the low at -$5.2 million in Q3 2024.
- The 5-year median for Cash from Investing Activities is -$48846.0 (2026), against an average of -$769063.8.
- The sharpest annual moves came in 2025 and 2026: Cash from Investing Activities plunged 5655.24% in 2025, then surged 95.76% in 2026.
- TuHURA Biosciences' Cash from Investing Activities stood at -$232000.0 in 2022, then soared by 91.38% to -$20000.0 in 2023, then slumped by 26044.34% to -$5.2 million in 2024, then soared by 99.47% to -$27850.0 in 2025, then tumbled by 75.39% to -$48846.0 in 2026.
- Business Quant data shows HURA's Cash from Investing Activities at -$48846.0 in Q1 2026, -$27850.0 in Q4 2025, and -$156464.0 in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | -45.80 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | -92.70 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 329.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | -49.35 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | -363.46 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -3.17 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 24.51 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | -229.72 Mn |
| 10 | TuHURA Biosciences | 37.61 Mn | 37.61 Mn | - | -136,978.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -48,846.00 |
| Mar 31, 2026 | -48,846.00 |
| Dec 31, 2025 | -27,850.00 |
| Dec 31, 2025 | -27,850.00 |
| Jun 30, 2025 | -156,464.00 |
| Jun 30, 2025 | -156,464.00 |
| Mar 31, 2025 | -1.15 Mn |
| Mar 31, 2025 | -1.15 Mn |
| Sep 30, 2024 | -5.23 Mn |
| Sep 30, 2024 | -5.23 Mn |
| Jun 30, 2024 | -36,498.00 |
| Jun 30, 2024 | -36,498.00 |
| Mar 31, 2024 | -20,000.00 |
| Mar 31, 2024 | -20,000.00 |
| Dec 31, 2023 | -20,000.00 |
| Dec 31, 2023 | -20,000.00 |
| Sep 30, 2022 | -232,000.00 |
| Sep 30, 2022 | -232,000.00 |
| Mar 31, 2021 | -8,000.00 |
| Mar 31, 2021 | -8,000.00 |